Increased incidence of interstitial pneumonia by CHOP combined with rituximab.

International Journal of Hematology
Daisuke EnnishiKiyohiko Hatake

Abstract

Several authors have reported interstitial pneumonia (IP) during rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, while others have encountered Pneumocystis jirovecii pneumonia during rituximab-combined bi-weekly CHOP. Herein, we report that 13 of 90 (14%) patients developed IP during R-CHOP therapy, compared with none of 105 patients treated with CHOP alone as a historical control. There were no differences in baseline data between patients undergoing the two therapies. Among R-CHOP-treated patients, serum beta-D-glucan was increased in 8 of 12 (75%) IP patients compared with none of 30 non-IP patients examined. In five IP patients who underwent sputum evaluation, two were positive for P. jirovecii by the polymerase chain reaction and another two were positive for Candida albicans. No other organisms were detected as causative pathogens. Treatment with steroids, sulfamethoxazole-trimethoprim (ST), and antifungals was effective. Our results suggest that R-CHOP raises the incidence of IP, possibly through increasing the susceptibility to P. jirovecii and fungal infection. The need for prophylactic antifungals and ST during R-CHOP should be evaluated by randomized controlled trials.

References

Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jun 27, 2003·The New England Journal of Medicine·Catherine BurtonRiaz Jan-Mohamed
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Zekaver OdabasiLuis Ostrosky-Zeichner
Aug 13, 2004·American Journal of Hematology·R SwordsP T Murphy
Oct 16, 2004·International Journal of Hematology·Bungo SaitoShigeru Tomoyasu
Oct 30, 2004·Leukemia & Lymphoma·Doru T AlexandrescuPeter H Wiernik
Mar 16, 2005·International Journal of Hematology·Junji HiragaTomoki Naoe
Apr 29, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H Ghesquieres
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis Ostrosky-ZeichnerJohn H Rex
Aug 16, 2005·European Journal of Cancer Care·K NakaseH Shiku
Apr 28, 2006·Clinical Lymphoma & Myeloma·Yair HerishanuElizabeth Naparstek

❮ Previous
Next ❯

Citations

Sep 6, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Mai SatoKentaro Matsuoka
Dec 14, 2011·Rheumatology·Andreas V HadjinicolaouAndrew J K Ostör
Dec 3, 2010·Journal of Clinical and Experimental Hematopathology : JCEH·Toshiro KurokawaTakashi Yoshida
Feb 20, 2014·Thyroid : Official Journal of the American Thyroid Association·Natsuko WatanabeKoichi Ito
Dec 2, 2010·Journal of Cancer Research and Therapeutics·Murali SubramanianK N Mohan Rao
Apr 29, 2009·Leukemia & Lymphoma·Ron RamPia Raanani
Mar 8, 2014·Advances in Chronic Kidney Disease·Ladan ZandFernando C Fervenza
Mar 31, 2010·Seminars in Hematology·Samantha M Jaglowski, John C Byrd
Mar 31, 2010·Seminars in Hematology·Juan C Gea-Banacloche
Apr 21, 2009·Clinics in Chest Medicine·Tamra M ArnoldChadi A Hage
Oct 8, 2011·Clinical Lymphoma, Myeloma & Leukemia·Harumi KatoYasuo Morishima
Nov 16, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Theodoros KelesidisSotirios Tsiodras
Apr 2, 2014·Therapeutic Advances in Musculoskeletal Disease·Jeremy M ClainUlrich Specks
Aug 12, 2017·International Reviews of Immunology·Evangelos A A ChristouFani Ladomenou
Jan 10, 2018·Journal of Pediatric Hematology/oncology·Najma Shaheen, Francis Mussai
Nov 19, 2010·Expert Review of Hematology·Ramón García-Sanz, Enrique M Ocio
Jan 9, 2021·Journal of Neurology·Clara Grazia ChisariFrancesco Patti
Mar 23, 2011·Archives of Dermatology·Christelle Le Roux-VilletHervé Bachelez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.